Trial Profile

Clinical trial of 1002 in Generalized Anxiety Disorder.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AM 1002 (Primary)
Indications Generalised anxiety disorder
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Nov 2025 New trial record
06 Oct 2025 According to Arcadia Medicine media release, the United States Food and Drug Administration (FDA) cleared the companys Investigational New Drug (IND) application and company plans to initiate a clinical trial of AM-1002 in this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com